Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Desvenlafaxine Succinate on Midazolam Pharmacokinetics in Healthy Subjects
NCT00952653Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jun 2010
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Pfizer. Primary endpoints: Midazolam Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time, Midazolam Maximum Observed Plasma Concentration and 2 more. Started Jun 2010; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00952653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00952653.